Cell Reports, Volume 35

Supplemental information

DHX15 is required to control RNA

virus-induced intestinal inflammation

Junji Xing, Xiaojing Zhou, Mingli Fang, Evan Zhang, Laurie J. Minze, and Zhiqiang Zhang





and poly dG:dC. Related to Figure 1.

(A) Immunoblot (IB) showing the knockdown efficiency of shRNAs targeting the indicated genes in HT-29 IECs. Nontargeting shRNA served as a control (sh-Ctrl). GAPDH blots are shown as loading controls. The position of protein markers (shown in kDa) is indicated on the right. (B-D) ELISA of IFN- β (B), IFN- λ 3 (C) and IL-18 (D) production from human HT-29 IECs with the indicated shRNA after a 20 h stimulation with 5 µg/ml poly I:C or 2.5 µg/ml poly dG:dC delivered by Lipofectamine 3000. N-STM, scrambled shRNA-treated HT-29 IECs without stimulation. Each circle represents an individual independent experiment and small solid black lines indicate the average of triplicates. NS, P>0.05, *P<0.05 (unpaired t test).



Figure S2. DHX15 positively regulates production of proinflammatory cytokines IL-6 and TNF-α in human HT-29 IECs after poly I:C

stimulation. Related to Figure 1.

(A-B) ELISA of IL-6 (A) and TNF- α (B) production from human HT-29 IECs with the indicated shRNA after a 20 h stimulation with 5 µg/ml poly I:C delivered by Lipofectamine 3000. N-STM, scrambled shRNA-treated HT-29 IECs without stimulation. Nontargeting shRNA served as a control (sh-Ctrl). Each circle represents an individual independent experiment and small solid black lines indicate the average of triplicates. NS, P>0.05, ***P<0.001 (unpaired t test).



Figure S3. DHX15 is required for IFN-β, IFN-λ3 and IL-18 production in human HT-29 IECs after infection with non-enteric RNA viruses.

Related to Figure 2.

(A-C) ELISA of IFN- β (A), IFN- λ 3 (B) and IL-18 (C) production from human HT-29 IECs with the indicated shRNA after a 20 h infection with nonenteric RNA viruses including vesicular stomatitis virus Indiana strain (VSV) and influenza A virus PR8 strain (Flu) at a multiplicity of infection (MOI) of 10. Mock, scrambled shRNA(sh-Ctrl)-treated human HT-29 IECs without virus infection. Each circle represents an individual independent experiment and small solid black lines indicate the average of triplicates. **0.001<P<0.01 (unpaired t test).



Figure S4. Dhx15 gene targeting. Related to Figure 3.

(A) Schematic picture of Dhx15 gene targeting using an FRT-LoxP vector, showing the exons 4 to 6 of Dhx15 gene. Targeted mice were crossed with FRT deleter (Rosa26-FLPe) mice to generate Dhx15-floxed ($Dhx15^{fl/fl}$) mice, which were further crossed with *Villin*-Cre transgenic mice to generate IEC-specific Dhx15-knockout mice, $Dhx15^{fl/fl}$; *Villin*-Cre ($Dhx15^{fl/fl}$).

(B) Genotyping PCR to amplify the *Dhx15-flox* (using P1/P2 primer pair) and WT (using P1/P2 primer pair) alleles (top), or the *Villin*-Cre (using 16775/oIMR9074 primer pair) and WT (using 16775/16776 primer pair) alleles (bottom).

(C) Immunoblot (IB) of DHX15 in mouse primary IECs from wild-type *Dhx15^{fl/fl}* and *Dhx15^{IEC-KO}* mice. The position of protein markers (shown in kDa) is indicated on the right.



Figure S5. DHX15 does not affect expression of differentiation markers EpCAM and E-Cadherin in mouse IECs. Related to Figure 3.

Flow cytometry analyzing the expression of differentiation markers EpCAM and E-Cadherin in the mouse primary IECs isolated from wild-type *Dhx15^{II/fl}* and *Dhx15^{IEC-KO}* mice using isotype control antibodies (Control, Ctrl), EpCAM-PE/Cyanine7 and E-Cadherin-PE antibodies. Flow cytometry data were acquired on a LSR-II flow cytometer (Beckton Dickinson) and analyzed using FlowJo v10 software (Tree Star).



Figure S6. IEC-specific DHX15 ablation does not affect expression of epithelial tight junction proteins. Related to Figure 3. (**A-D**) The qRT-PCR analysis of the expression of tight junction-related genes E-cadherin (**A**), Claudin-2 (**B**), Occludin (**C**), and Zonula occludens-1 (ZO-1, **D**) in the mouse primary IECs isolated from wild-type *Dhx15*^{fl/fl} and *Dhx15*^{fl/C-KO} mice. mRNA, messenger RNA. NS, not significant.





(C-D) The absolute cell numbers in spleen (C) and mLN (D) from wild-type Dhx15^{fl/fl} and Dhx15^{/EC-KO} mice (n=3 mice) for representative flow cytometry data in A and B. NS, not significant (unpaired t test).

(E) Representative FACS plots showing the gating strategy for analyzing T, B, and NK cell population in spleen of the mice. Flow cytometry data were acquired on a LSR-II flow cytometer (Beckton Dickinson) and analyzed using FlowJo v10 software (Tree Star).



Figure S8. DHX15 positively regulates production of IFN-β, IFN-λ3 and IL-18 in mouse primary IECs after infection with non-enteric RNA

viruses. Related to Figure 3.



Figure S9. DHX15 recruits MAVS and NLRP6 to form signaling complex in mouse IECs after reovirus infection. Related to Figure 6.

(A) Quantification of immunoblot bands of DHX15 immunoprecipitated (IP) by NLRP6 in top panel of Fig. 6A expressed as relative to lane 1 using the densitometric analysis by ImageJ software; n=3 blots.

(B) Quantification of immunoblot bands of cleaved IL-18 in fifth panel of Fig. 6E expressed as relative to lane 2 using the densitometric analysis by ImageJ software; n=3 blots. NS, not significant, ***P<0.001, ****P<0.0001 (unpaired t test).

(C) Immunoblot (IB) analysis of the expression of RNA sensors including DHX15, DHX9, RIG-I and MDA5 and adaptors including MAVS, NLRP6 and NLRP9 in mouse primary IECs from wild-type *Dhx15*^{II/II} and *Dhx15*^{IEC-KO} mice without or with reovirus infection at MOI of 1 for 1 hour.

(**D**) Immunoblot analysis of endogenous proteins of NLRP6, DHX15, MAVS, RIG-I and MDA5 precipitated with anti-NLRP6 or control IgG from wholecell lysates of mouse IECs from wild-type *Dhx15*^{fl/fl} mice infected with reovirus at MOI of 10 for 6 hours. The position of protein markers (shown in kDa) is indicated on the right.

Gene	Sequence
qRT-PCR	
Human <i>Gapdh</i>	F: 5'- GGAGCGAGATCCCTCCAAAAT -3'
	R: 5'- GGCTGTTGTCATACTTCTCATGG -3'
Mouse Ifnb	F: 5'- CCCTATGGAGATGACGGAGA -3'
	R: 5'- TCCCACGTCAATCTTTCCTC -3'
Mouse Ifnl2/3	F: 5'- AGTGGAAGCAAAGGATTG -3'
	R: 5'- GAGATGAGGTGGGAACTG -3'
Mouse II18	F: 5'- GCCTCAAACCTTCCAAATCA -3'
	R: 5'- TGGATCCATTTCCTCAAAGG -3'
Mouse Gapdh	F: 5'- AGGTCGGTGTGAACGGATTTG -3'
	R: 5'- TGTAGACCATGTAGTTGAGGTCA -3'
Mouse Hprt	F: 5'- CACAGGACTAGAACACCTGC -3'
	R: 5'- GCTGGTGAAAAGGACCTCT -3'
Mouse E-cadherin	F: 5'- CACCTGGAGAGAGGCCATGT -3'
	R: 5'- TGGGAAACATGAGCAGCTCT-3'
Mouse Claudin-2	F: 5'- TATGTTGGTGCCAGCATTGT-3'
	R: 5'- TCATGCCCACCAGAGATA-3'
Mouse Occludin	F: 5'- CCTCCAATGGCAAAGTGAAT-3'
	R: 5'- CTCCCCACCTGTCGTGTAGT-3'
Mouse ZO-1	F: 5'- CCACCTCTGTCCAGCTCTTC -3'
	R: 5'- CACCGGAGTGATGGTTTTCT -3'
Mouse <i>β-actin</i>	F: 5'- CGTGAAAAGATGACCCAGATCA -3'
	R: 5'- CACAGCCTGGATGGCTACGT -3'
Rotavirus NSP5	F: 5'- TTCTGCTTCAAACGAYCCACTC -3'
	R: 5'- GAGAAATCYACTTGRTCGCA -3'
Reovirus S4	F: 5'- GGAACATTGTGAGAGCAGCA -3'
	R: 5'- GCAAGCTAGTGGAGGCAGTC -3'
HSV-1 VP16	F: 5'- TCGGCGTGGAAGAAACGAGAGA -3'
	R: 5'- CGAACGCACCCAAATCGACA -3'
Dhx15 genotype PCR	
P1	5'-CACCCAAGTATCAGTATTCTCACG -3'
P2	5'-GCAATAATGTAACACAGCTAACAGC -3'
P3	5'-GATTGGTTTCTCTAATTGCTAGCC -3'
P4	5'-CACTGTGTGAGTTCAAGAATCACC -3'
Villin-Cre genotype PCR	
Common primer 16775	5'-GCCTTCTCCTCTAGGCTCGT -3'
WT primer 16776	5'-TATAGGGCAGAGCTGGAGGA -3'
Mutant primer oIMR9074	5'-AGGCAAATTTTGGTGTACGG -3'

 Table S1. Primers for qRT-PCR and genotype PCR used in this study. Related to STAR Methods.